RxSight (RXST) Financials

$15.68 -0.21 (-1.32%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$15.68 +0.01 (+0.03%)

As of 05/23/2025 04:04 PM Eastern

Annual Income Statements for RxSight

This table shows RxSight's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-27	-49	-67
Consolidated Net Income / (Loss)	-27	-49	-67
Net Income / (Loss) Continuing Operations	-27	-49	-67
Total Pre-Tax Income	-27	-49	-67
Total Operating Income	-37	-50	-63
Total Gross Profit	99	54	21
Total Revenue	140	89	49
Operating Revenue	140	89	49
Total Cost of Revenue	41	35	28
Operating Cost of Revenue	41	35	28
Total Operating Expenses	136	104	85
Selling, General & Admin Expense	101	75	59
Research & Development Expense	34	29	26
Total Other Income / (Expense), net	9.45	1.50	-3.43
Interest Expense	0.02	5.08	4.95
Interest & Investment Income	9.47	6.57	1.52
Income Tax Expense	0.05	0.02	0.01
Basic Earnings per Share	($0.71)	($1.41)	($2.41)
Weighted Average Basic Shares Outstanding	38.87M	34.46M	27.66M
Diluted Earnings per Share	($0.71)	($1.41)	($2.41)
Weighted Average Diluted Shares Outstanding	38.87M	34.46M	27.66M
Weighted Average Basic & Diluted Shares Outstanding	40.49M	36.99M	33.78M

This table shows RxSight's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-5.94	-6.34	-6.08	-9.10	-9.18	-12	-14	-13	-16	-17
Consolidated Net Income / (Loss)	-5.94	-6.34	-6.08	-9.10	-9.18	-12	-14	-13	-16	-17
Net Income / (Loss) Continuing Operations	-5.94	-6.34	-6.08	-9.10	-9.18	-12	-14	-13	-16	-17
Total Pre-Tax Income	-5.93	-6.33	-6.06	-9.09	-9.20	-12	-14	-13	-16	-17
Total Operating Income	-8.63	-9.23	-8.33	-11	-11	-13	-14	-13	-15	-16
Total Gross Profit	29	25	24	21	18	14	12	10	7.42	5.36
Total Revenue	40	35	35	30	29	22	21	17	16	13
Operating Revenue	40	35	35	30	29	22	21	17	16	13
Total Cost of Revenue	11	10	11	8.83	11	8.47	8.80	7.12	8.67	7.26
Operating Cost of Revenue	11	10	11	8.83	11	8.47	8.80	7.12	8.67	7.26
Total Operating Expenses	37	34	33	31	29	26	26	23	22	21
Selling, General & Admin Expense	28	26	24	23	21	19	18	16	16	15
Research & Development Expense	9.21	8.84	8.29	8.03	7.34	7.10	7.40	7.21	6.68	6.39
Total Other Income / (Expense), net	2.70	2.90	2.27	1.58	1.66	0.11	-0.15	-0.12	-0.62	-0.86
Interest Expense	0.00	0.01	0.01	0.01	0.00	1.64	1.93	1.51	1.45	1.30
Interest & Investment Income	2.71	2.91	2.28	1.59	1.66	1.75	1.78	1.39	0.84	0.44
Income Tax Expense	0.01	0.01	0.02	0.01	-0.02	0.01	0.03	0.00	0.01	0.00
Basic Earnings per Share	($0.14)	($0.16)	($0.16)	($0.25)	($0.24)	($0.35)	($0.40)	($0.42)	($0.55)	($0.61)
Weighted Average Basic Shares Outstanding	38.87M	39.79M	38.46M	36.84M	34.46M	35.66M	34.50M	31.64M	27.66M	27.67M
Diluted Earnings per Share	($0.14)	($0.16)	($0.16)	($0.25)	($0.24)	($0.35)	($0.40)	($0.42)	($0.55)	($0.61)
Weighted Average Diluted Shares Outstanding	38.87M	39.79M	38.46M	36.84M	34.46M	35.66M	34.50M	31.64M	27.66M	27.67M
Weighted Average Basic & Diluted Shares Outstanding	40.49M	40.30M	39.68M	37.20M	36.99M	35.86M	35.64M	33.98M	33.78M	27.72M

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	7.05	-2.19	-13
Net Cash From Operating Activities	-17	-42	-59
Net Cash From Continuing Operating Activities	-17	-42	-59
Net Income / (Loss) Continuing Operations	-27	-49	-67
Consolidated Net Income / (Loss)	-27	-49	-67
Depreciation Expense	3.58	4.08	3.88
Amortization Expense	-8.93	-5.67	-0.72
Non-Cash Adjustments To Reconcile Net Income	25	18	12
Changes in Operating Assets and Liabilities, net	-9.21	-9.07	-7.41
Net Cash From Investing Activities	-99	-22	40
Net Cash From Continuing Investing Activities	-99	-22	40
Purchase of Property, Plant & Equipment	-5.44	-4.81	-2.39
Purchase of Investments	-337	-272	-213
Sale and/or Maturity of Investments	243	255	255
Net Cash From Financing Activities	123	62	6.33
Net Cash From Continuing Financing Activities	123	62	6.33
Repayment of Debt	0.00	-62	-0.15
Repurchase of Common Equity	-0.77	-0.62	-0.59
Issuance of Debt	0.00	20	0.00
Issuance of Common Equity	129	106	7.83
Other Financing Activities, net	-4.83	-1.58	-0.76
Effect of Exchange Rate Changes	-0.01	0.01	-0.01
Cash Interest Paid	0.02	3.48	4.26
Cash Income Taxes Paid	0.02	0.01	0.00

This table details how cash moves in and out of RxSight's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	0.02	-7.73	-8.20	23	-0.17	1.06	-2.26	-0.82	2.87	-15
Net Cash From Operating Activities	-4.26	0.65	-4.03	-9.31	-8.30	-7.98	-7.55	-18	-14	-15
Net Cash From Continuing Operating Activities	-4.29	0.65	-4.03	-9.31	-8.30	-7.98	-7.55	-18	-14	-15
Net Income / (Loss) Continuing Operations	-5.94	-6.34	-6.08	-9.10	-9.18	-12	-14	-13	-16	-17
Consolidated Net Income / (Loss)	-5.94	-6.34	-6.08	-9.10	-9.18	-12	-14	-13	-16	-17
Depreciation Expense	0.52	1.13	0.81	1.12	1.05	1.08	0.99	0.96	0.92	0.94
Amortization Expense	-2.62	-2.76	-2.07	-1.48	-1.54	-1.54	-1.51	-1.07	-0.60	-0.21
Non-Cash Adjustments To Reconcile Net Income	7.32	6.75	6.16	4.81	4.58	5.48	4.32	3.31	3.23	3.22
Changes in Operating Assets and Liabilities, net	-3.57	1.87	-2.86	-4.65	-3.21	-0.59	2.46	-7.74	-1.83	-2.32
Net Cash From Investing Activities	1.32	-9.26	-116	24	4.57	17	4.40	-48	10	0.56
Net Cash From Continuing Investing Activities	1.32	-9.26	-116	24	4.57	17	4.40	-48	10	0.56
Purchase of Property, Plant & Equipment	-0.85	-1.10	-1.52	-1.97	-1.59	-0.65	-1.82	-0.75	-0.36	-0.58
Purchase of Investments	-53	-77	-159	-48	-44	-72	-49	-108	-34	-74
Sale and/or Maturity of Investments	55	69	45	74	50	90	55	60	45	75
Net Cash From Financing Activities	2.98	0.88	111	7.99	3.56	-8.23	0.89	65	6.31	-0.46
Net Cash From Continuing Financing Activities	2.98	0.88	111	7.99	3.56	-8.23	0.89	65	6.31	-0.46
Issuance of Common Equity	2.99	3.84	112	10	3.58	14	23	66	6.64	0.15
Other Financing Activities, net	-0.01	-2.65	-0.01	-2.16	-0.04	-1.12	-0.04	-0.38	-0.04	-0.30
Effect of Exchange Rate Changes	-0.01	0.01	-0.00	-0.00	0.01	-0.01	0.00	0.00	0.01	-0.01
Cash Interest Paid	0.01	0.01	0.01	0.01	0.00	0.23	1.90	1.35	1.22	1.13
Cash Income Taxes Paid	-0.00	0.00	0.02	0.00	-0.00	-	0.01	0.00	-	-

This table presents RxSight's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	319	183	150
Total Current Assets	294	168	135
Cash & Equivalents	17	9.69	12
Short-Term Investments	221	117	94
Accounts Receivable	30	20	11
Inventories, net	22	17	15
Prepaid Expenses	4.54	3.52	2.96
Plant, Property, & Equipment, net	12	11	10
Total Noncurrent Assets	12	3.30	5.47
Other Noncurrent Operating Assets	12	3.30	5.47
Total Liabilities & Shareholders' Equity	319	183	150
Total Liabilities	37	22	60
Total Current Liabilities	26	21	17
Accounts Payable	4.54	3.86	2.60
Accrued Expenses	20	15	13
Other Current Liabilities	0.97	1.80	1.97
Total Noncurrent Liabilities	11	1.29	43
Long-Term Debt	0.13	0.07	40
Capital Lease Obligations	11	1.21	2.86
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	281	160	90
Total Preferred & Common Equity	281	160	90
Preferred Stock	0.00	0.00	0.00
Total Common Equity	281	160	90
Common Stock	903	755	636
Retained Earnings	-622	-595	-546
Accumulated Other Comprehensive Income / (Loss)	0.17	-0.01	-0.10

This table presents RxSight's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	310	305	183	182	195	203	156
Total Current Assets	287	281	169	168	180	188	139
Cash & Equivalents	17	24	33	9.86	8.75	11	8.91
Short-Term Investments	220	209	93	122	138	143	104
Accounts Receivable	25	26	22	15	13	13	9.02
Inventories, net	22	19	19	19	18	18	15
Prepaid Expenses	2.61	2.77	2.96	1.90	2.11	2.99	1.97
Plant, Property, & Equipment, net	12	12	12	10	11	9.80	11
Total Noncurrent Assets	11	12	2.99	3.64	4.28	5.06	5.92
Other Noncurrent Operating Assets	11	12	2.99	3.64	4.28	5.06	5.92
Total Liabilities & Shareholders' Equity	310	305	183	182	195	203	156
Total Liabilities	33	30	19	20	38	58	60
Total Current Liabilities	23	20	18	19	17	15	16
Accounts Payable	4.58	5.10	5.06	4.11	4.00	3.72	4.17
Accrued Expenses	17	14	12	13	11	9.18	10
Other Current Liabilities	0.73	0.74	1.61	1.98	1.98	1.98	1.95
Total Noncurrent Liabilities	11	11	0.91	1.43	22	43	43
Long-Term Debt	0.00	0.00	0.00	0.08	20	40	40
Capital Lease Obligations	11	11	0.91	1.35	1.84	2.34	3.35
Other Noncurrent Operating Liabilities	0.00	0.00	0.00	0.00	-	-	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	277	275	164	161	157	145	96
Total Preferred & Common Equity	277	275	164	161	157	145	96
Preferred Stock	0.00	0.00	0.00	0.00	0.00	-	0.00
Total Common Equity	277	275	164	161	157	145	96
Common Stock	893	885	768	747	730	704	627
Retained Earnings	-616	-610	-604	-585	-573	-559	-530
Accumulated Other Comprehensive Income / (Loss)	0.52	-0.12	-0.05	-0.06	-0.07	-0.01	-0.14

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	57.09%	81.77%	116.90%
EBITDA Growth	18.32%	14.09%	-17.82%
EBIT Growth	26.41%	20.90%	-14.08%
NOPAT Growth	26.41%	20.90%	-19.95%
Net Income Growth	43.52%	27.19%	-37.11%
EPS Growth	49.65%	41.49%	32.49%
Operating Cash Flow Growth	59.26%	29.32%	-31.63%
Free Cash Flow Firm Growth	-10.38%	13.71%	-14.30%
Invested Capital Growth	60.93%	27.06%	21.57%
Revenue Q/Q Growth	9.07%	16.31%	18.53%
EBITDA Q/Q Growth	1.42%	6.04%	13.40%
EBIT Q/Q Growth	5.69%	7.63%	13.79%
NOPAT Q/Q Growth	5.69%	7.63%	-0.52%
Net Income Q/Q Growth	10.55%	11.69%	0.18%
EPS Q/Q Growth	12.35%	18.02%	-97.54%
Operating Cash Flow Q/Q Growth	19.25%	11.78%	-9.55%
Free Cash Flow Firm Q/Q Growth	0.51%	0.19%	0.00%
Invested Capital Q/Q Growth	9.37%	11.08%	2.35%
Profitability Metrics	-	-	-
Gross Margin	70.71%	60.36%	43.52%
EBITDA Margin	-30.17%	-58.01%	-122.74%
Operating Margin	-26.34%	-56.23%	-129.21%
EBIT Margin	-26.34%	-56.23%	-129.21%
Profit (Net Income) Margin	-19.62%	-54.57%	-136.22%
Tax Burden Percent	100.18%	100.04%	100.01%
Interest Burden Percent	74.35%	97.01%	105.42%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-57.38%	-113.85%	-179.31%
ROIC Less NNEP Spread (ROIC-NNEP)	-56.44%	-99.49%	-154.20%
Return on Net Nonoperating Assets (RNNOA)	44.95%	75.00%	120.79%
Return on Equity (ROE)	-12.43%	-38.85%	-58.52%
Cash Return on Invested Capital (CROIC)	-104.08%	-137.68%	-198.78%
Operating Return on Assets (OROA)	-14.71%	-30.11%	-36.93%
Return on Assets (ROA)	-10.96%	-29.22%	-38.94%
Return on Common Equity (ROCE)	-12.43%	-38.85%	-58.52%
Return on Equity Simple (ROE_SIMPLE)	-9.76%	-30.31%	-74.25%
Net Operating Profit after Tax (NOPAT)	-26	-35	-44
NOPAT Margin	-18.44%	-39.36%	-90.45%
Net Nonoperating Expense Percent (NNEP)	-0.94%	-14.36%	-25.11%
Return On Investment Capital (ROIC_SIMPLE)	-8.82%	-21.69%	-33.34%
Cost of Revenue to Revenue	29.29%	39.64%	56.48%
SG&A Expenses to Revenue	72.49%	83.97%	119.71%
R&D to Revenue	24.56%	32.61%	53.02%
Operating Expenses to Revenue	97.05%	116.58%	172.73%
Earnings before Interest and Taxes (EBIT)	-37	-50	-63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-42	-52	-60
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	4.93	9.02	3.91
Price to Tangible Book Value (P/TBV)	4.93	9.02	3.91
Price to Revenue (P/Rev)	9.90	16.23	7.17
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.91	38.30	10.63
Enterprise Value to Revenue (EV/Rev)	8.29	14.82	5.89
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.04	0.01	0.48
Long-Term Debt to Equity	0.04	0.01	0.48
Financial Leverage	-0.80	-0.75	-0.78
Leverage Ratio	1.13	1.33	1.50
Compound Leverage Factor	0.84	1.29	1.58
Debt to Total Capital	3.91%	0.79%	32.37%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	3.91%	0.79%	32.37%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.09%	99.21%	67.63%
Debt to EBITDA	-0.27	-0.02	-0.72
Net Debt to EBITDA	5.35	2.44	1.04
Long-Term Debt to EBITDA	-0.27	-0.02	-0.72
Debt to NOPAT	-0.44	-0.04	-0.97
Net Debt to NOPAT	8.75	3.59	1.42
Long-Term Debt to NOPAT	-0.44	-0.04	-0.97
Altman Z-Score	20.61	35.09	-1.72
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	11.36	8.06	7.81
Quick Ratio	10.33	7.05	6.77
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-47	-42	-49
Operating Cash Flow to CapEx	-311.51%	-864.00%	-2,459.26%
Free Cash Flow to Firm to Interest Expense	-2,228.55	-8.35	-9.93
Operating Cash Flow to Interest Expense	-806.95	-8.19	-11.90
Operating Cash Flow Less CapEx to Interest Expense	-1,066.00	-9.14	-12.38
Efficiency Ratios	-	-	-
Asset Turnover	0.56	0.54	0.29
Accounts Receivable Turnover	5.56	5.70	6.20
Inventory Turnover	2.08	2.19	2.42
Fixed Asset Turnover	12.03	8.49	4.59
Accounts Payable Turnover	9.75	10.94	12.92
Days Sales Outstanding (DSO)	65.64	64.00	58.91
Days Inventory Outstanding (DIO)	175.58	166.71	150.78
Days Payable Outstanding (DPO)	37.44	33.38	28.25
Cash Conversion Cycle (CCC)	203.79	197.33	181.44
Capital & Investment Metrics	-	-	-
Invested Capital	55	34	27
Invested Capital Turnover	3.11	2.89	1.98
Increase / (Decrease) in Invested Capital	21	7.34	4.81
Enterprise Value (EV)	1,160	1,320	288
Market Capitalization	1,386	1,446	351
Book Value per Share	$6.98	$4.47	$3.24
Tangible Book Value per Share	$6.98	$4.47	$3.24
Total Capital	293	162	133
Total Debt	11	1.29	43
Total Long-Term Debt	11	1.29	43
Net Debt	-226	-126	-63
Capital Expenditures (CapEx)	5.44	4.81	2.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)	31	20	12
Debt-free Net Working Capital (DFNWC)	268	148	117
Net Working Capital (NWC)	268	148	117
Net Nonoperating Expense (NNE)	1.65	14	22
Net Nonoperating Obligations (NNO)	-226	-126	-63
Total Depreciation and Amortization (D&A)	-5.35	-1.59	3.17
Debt-free, Cash-free Net Working Capital to Revenue	21.96%	22.81%	23.50%
Debt-free Net Working Capital to Revenue	191.49%	165.59%	239.40%
Net Working Capital to Revenue	191.49%	165.59%	239.40%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.71)	($1.41)	($2.41)
Adjusted Weighted Average Basic Shares Outstanding	38.87M	34.46M	27.66M
Adjusted Diluted Earnings per Share	($0.71)	($1.41)	($2.41)
Adjusted Weighted Average Diluted Shares Outstanding	38.87M	34.46M	27.66M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.49M	36.99M	33.78M
Normalized Net Operating Profit after Tax (NOPAT)	-26	-35	-44
Normalized NOPAT Margin	-18.44%	-39.36%	-90.45%
Pre Tax Income Margin	-19.59%	-54.55%	-136.20%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-1,755.14	-9.87	-12.80
NOPAT to Interest Expense	-1,228.60	-6.91	-8.96
EBIT Less CapEx to Interest Expense	-2,014.19	-10.81	-13.29
NOPAT Less CapEx to Interest Expense	-1,487.65	-7.85	-9.45
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.80%	-1.28%	-0.88%

This table displays calculated financial ratios and metrics derived from RxSight's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	40.71%	59.08%	67.65%	68.75%	77.64%	75.97%	83.19%	95.58%	90.93%	118.03%
EBITDA Growth	5.38%	16.30%	32.25%	16.49%	22.66%	14.82%	4.37%	14.53%	38.82%	-45.41%
EBIT Growth	20.48%	26.26%	38.84%	18.53%	27.61%	21.59%	13.72%	21.00%	40.31%	-37.46%
NOPAT Growth	20.48%	26.26%	38.84%	18.53%	27.61%	21.59%	13.72%	21.00%	-2.23%	-21.71%
Net Income Growth	35.29%	48.95%	55.96%	31.12%	41.21%	26.18%	17.50%	24.91%	0.78%	-32.71%
EPS Growth	41.67%	54.29%	60.00%	40.48%	56.36%	42.62%	34.43%	34.38%	-185.94%	10.29%
Operating Cash Flow Growth	48.68%	108.14%	46.63%	47.60%	40.08%	47.45%	49.09%	-18.55%	-58.84%	-10.42%
Free Cash Flow Firm Growth	-81.04%	-96.84%	-67.23%	34.90%	2.42%	-16.74%	-13.80%	40.49%	0.00%	67.93%
Invested Capital Growth	60.93%	63.45%	66.43%	17.10%	27.06%	17.07%	25.92%	49.48%	21.57%	0.78%
Revenue Q/Q Growth	13.88%	1.22%	18.21%	3.26%	28.74%	6.67%	18.99%	8.71%	27.53%	11.05%
EBITDA Q/Q Growth	1.12%	-13.25%	13.13%	2.72%	12.54%	8.33%	-7.08%	9.91%	3.66%	-2.91%
EBIT Q/Q Growth	6.47%	-10.72%	21.90%	1.67%	13.28%	8.17%	-4.03%	12.63%	6.07%	-1.05%
NOPAT Q/Q Growth	6.47%	-10.72%	21.90%	1.67%	13.28%	8.17%	-4.03%	12.63%	6.07%	-1.05%
Net Income Q/Q Growth	6.31%	-4.26%	33.20%	0.84%	26.08%	10.06%	-4.48%	15.36%	7.18%	-0.51%
EPS Q/Q Growth	12.50%	0.00%	36.00%	-4.17%	31.43%	12.50%	4.76%	23.64%	9.84%	0.00%
Operating Cash Flow Q/Q Growth	-755.38%	116.14%	56.74%	-12.14%	-4.00%	-5.78%	57.52%	-28.22%	8.78%	-2.46%
Free Cash Flow Firm Q/Q Growth	-3.43%	2.55%	-102.70%	11.39%	-12.46%	17.21%	21.09%	-32.82%	-34.54%	19.30%
Invested Capital Q/Q Growth	9.37%	-3.59%	33.21%	14.56%	11.08%	-1.83%	-6.27%	24.30%	2.35%	5.60%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	71.59%	71.42%	69.51%	70.09%	61.77%	61.85%	57.74%	59.27%	46.14%	42.46%
EBITDA Margin	-26.69%	-30.74%	-27.48%	-37.39%	-39.69%	-58.43%	-67.99%	-75.56%	-91.17%	-120.70%
Operating Margin	-21.46%	-26.13%	-23.89%	-36.15%	-37.97%	-56.36%	-65.47%	-74.89%	-93.18%	-126.50%
EBIT Margin	-21.46%	-26.13%	-23.89%	-36.15%	-37.97%	-56.36%	-65.47%	-74.89%	-93.18%	-126.50%
Profit (Net Income) Margin	-14.77%	-17.95%	-17.42%	-30.83%	-32.11%	-55.93%	-66.33%	-75.54%	-97.03%	-133.32%
Tax Burden Percent	100.20%	100.21%	100.26%	100.10%	99.80%	100.10%	100.19%	100.00%	100.03%	100.00%
Interest Burden Percent	68.68%	68.56%	72.76%	85.20%	84.74%	99.13%	101.12%	100.88%	104.10%	105.39%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-46.74%	-57.41%	-45.74%	-69.91%	-76.88%	-105.05%	-108.32%	-107.22%	-129.31%	-138.67%
ROIC Less NNEP Spread (ROIC-NNEP)	-46.80%	-57.48%	-45.60%	-68.53%	-75.20%	-101.39%	-104.26%	-103.41%	-123.58%	-132.85%
Return on Net Nonoperating Assets (RNNOA)	37.27%	46.77%	36.72%	52.29%	56.70%	78.73%	82.13%	81.71%	96.80%	104.43%
Return on Equity (ROE)	-9.47%	-10.64%	-9.02%	-17.62%	-20.18%	-26.32%	-26.18%	-25.52%	-32.51%	-34.24%
Cash Return on Invested Capital (CROIC)	-104.08%	-115.10%	-120.31%	-106.90%	-137.68%	-147.68%	-165.34%	-188.53%	-198.78%	0.00%
Operating Return on Assets (OROA)	-11.98%	-13.62%	-10.99%	-18.95%	-20.33%	-25.58%	-24.24%	-22.71%	-26.63%	-29.10%
Return on Assets (ROA)	-8.25%	-9.35%	-8.02%	-16.17%	-17.19%	-25.38%	-24.56%	-22.91%	-27.73%	-30.67%
Return on Common Equity (ROCE)	-9.47%	-10.64%	-9.02%	-17.62%	-20.18%	-26.32%	-26.18%	-25.52%	-32.51%	-34.24%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-11.07%	-13.36%	-27.14%	0.00%	-34.09%	-37.82%	-43.01%	0.00%	-69.70%
Net Operating Profit after Tax (NOPAT)	-6.04	-6.46	-5.83	-7.47	-7.60	-8.76	-9.54	-9.17	-10	-11
NOPAT Margin	-15.02%	-18.29%	-16.72%	-25.31%	-26.58%	-39.45%	-45.83%	-52.42%	-65.22%	-88.55%
Net Nonoperating Expense Percent (NNEP)	0.06%	0.07%	-0.14%	-1.38%	-1.68%	-3.66%	-4.05%	-3.82%	-5.73%	-5.82%
Return On Investment Capital (ROIC_SIMPLE)	-2.06%	-	-	-	-4.70%	-	-	-	-7.89%	-
Cost of Revenue to Revenue	28.41%	28.58%	30.49%	29.91%	38.23%	38.15%	42.26%	40.73%	53.86%	57.54%
SG&A Expenses to Revenue	70.15%	72.52%	69.63%	79.03%	74.05%	86.23%	87.65%	92.94%	97.78%	118.32%
R&D to Revenue	22.90%	25.03%	23.77%	27.21%	25.69%	31.99%	35.56%	41.21%	41.53%	50.64%
Operating Expenses to Revenue	93.04%	97.54%	93.40%	106.24%	99.74%	118.22%	123.21%	134.16%	139.32%	168.96%
Earnings before Interest and Taxes (EBIT)	-8.63	-9.23	-8.33	-11	-11	-13	-14	-13	-15	-16
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-11	-11	-9.59	-11	-11	-13	-14	-13	-15	-15
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	4.93	7.07	8.13	11.64	9.02	6.16	6.23	3.89	3.91	3.46
Price to Tangible Book Value (P/TBV)	4.93	7.07	8.13	11.64	9.02	6.16	6.23	3.89	3.91	3.46
Price to Revenue (P/Rev)	9.90	15.29	19.43	18.87	16.23	12.98	14.61	9.79	7.17	8.02
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	20.91	34.21	38.32	45.17	38.30	27.84	26.99	13.41	10.63	9.89
Enterprise Value to Revenue (EV/Rev)	8.29	13.52	17.50	17.64	14.82	11.28	12.73	7.86	5.89	6.34
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.04	0.04	0.04	0.01	0.01	0.01	0.14	0.29	0.48	0.45
Long-Term Debt to Equity	0.04	0.04	0.04	0.01	0.01	0.01	0.14	0.29	0.48	0.45
Financial Leverage	-0.80	-0.81	-0.81	-0.76	-0.75	-0.78	-0.79	-0.79	-0.78	-0.79
Leverage Ratio	1.13	1.12	1.16	1.25	1.33	1.31	1.35	1.42	1.50	1.46
Compound Leverage Factor	0.78	0.77	0.84	1.06	1.13	1.30	1.37	1.43	1.56	1.53
Debt to Total Capital	3.91%	3.67%	3.73%	0.55%	0.79%	0.88%	12.04%	22.73%	32.37%	31.13%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	3.91%	3.67%	3.73%	0.55%	0.79%	0.88%	12.04%	22.73%	32.37%	31.13%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	96.09%	96.33%	96.27%	99.45%	99.21%	99.12%	87.96%	77.27%	67.63%	68.87%
Debt to EBITDA	-0.27	-0.25	-0.24	-0.02	-0.02	-0.03	-0.38	-0.74	-0.72	-0.62
Net Debt to EBITDA	5.35	5.29	4.95	2.51	2.44	2.37	2.19	1.92	1.04	1.00
Long-Term Debt to EBITDA	-0.27	-0.25	-0.24	-0.02	-0.02	-0.03	-0.38	-0.74	-0.72	-0.62
Debt to NOPAT	-0.44	-0.39	-0.36	-0.03	-0.04	-0.04	-0.53	-1.02	-0.97	-0.98
Net Debt to NOPAT	8.75	8.28	7.51	3.73	3.59	3.44	3.11	2.66	1.42	1.58
Long-Term Debt to NOPAT	-0.44	-0.39	-0.36	-0.03	-0.04	-0.04	-0.53	-1.02	-0.97	-0.98
Altman Z-Score	20.90	34.00	42.85	56.24	35.80	25.95	12.43	3.11	-0.66	-0.56
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	11.36	12.67	14.33	9.20	8.06	8.87	10.89	12.62	7.81	8.50
Quick Ratio	10.33	11.60	13.20	8.02	7.05	7.77	9.68	11.20	6.77	7.44
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-27	-26	-27	-13	-15	-13	-16	-20	-15	-11
Operating Cash Flow to CapEx	-502.95%	58.93%	-264.41%	-473.26%	-521.75%	-1,222.36%	-413.93%	-2,378.05%	-3,827.07%	-2,618.62%
Free Cash Flow to Firm to Interest Expense	-6,759.83	-5,228.64	-4,471.18	-2,205.83	-4,978.57	-8.11	-8.31	-13.49	-10.55	-8.76
Operating Cash Flow to Interest Expense	-1,065.00	130.00	-671.17	-1,551.50	-2,767.00	-4.88	-3.91	-11.79	-9.55	-11.69
Operating Cash Flow Less CapEx to Interest Expense	-1,276.75	-90.60	-925.00	-1,879.33	-3,297.33	-5.27	-4.85	-12.28	-9.80	-12.14
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.56	0.52	0.46	0.52	0.54	0.45	0.37	0.30	0.29	0.23
Accounts Receivable Turnover	5.56	6.32	5.90	5.91	5.70	6.31	6.64	6.29	6.20	6.18
Inventory Turnover	2.08	1.99	2.08	2.01	2.19	1.93	2.15	2.23	2.42	1.98
Fixed Asset Turnover	12.03	11.40	10.03	9.44	8.49	7.34	6.20	5.56	4.59	3.66
Accounts Payable Turnover	9.75	9.32	8.55	8.44	10.94	7.99	8.76	9.40	12.92	8.38
Days Sales Outstanding (DSO)	65.64	57.77	61.82	61.77	64.00	57.82	54.96	58.01	58.91	59.05
Days Inventory Outstanding (DIO)	175.58	183.01	175.60	181.27	166.71	189.18	169.46	163.63	150.78	184.05
Days Payable Outstanding (DPO)	37.44	39.16	42.70	43.26	33.38	45.70	41.69	38.84	28.25	43.55
Cash Conversion Cycle (CCC)	203.79	201.63	194.72	199.78	197.33	201.29	182.73	182.80	181.44	199.55
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	55	51	53	39	34	31	32	34	27	27
Invested Capital Turnover	3.11	3.14	2.74	2.76	2.89	2.66	2.36	2.05	1.98	1.57
Increase / (Decrease) in Invested Capital	21	20	21	5.77	7.34	4.52	6.51	11	4.81	0.21
Enterprise Value (EV)	1,160	1,735	2,015	1,783	1,320	864	853	452	288	262
Market Capitalization	1,386	1,962	2,238	1,908	1,446	994	979	563	351	332
Book Value per Share	$6.98	$6.99	$7.40	$4.43	$4.47	$4.53	$4.63	$4.29	$3.24	$3.47
Tangible Book Value per Share	$6.98	$6.99	$7.40	$4.43	$4.47	$4.53	$4.63	$4.29	$3.24	$3.47
Total Capital	293	288	286	165	162	163	179	188	133	139
Total Debt	11	11	11	0.91	1.29	1.43	22	43	43	43
Total Long-Term Debt	11	11	11	0.91	1.29	1.43	22	43	43	43
Net Debt	-226	-227	-223	-124	-126	-130	-126	-111	-63	-69
Capital Expenditures (CapEx)	0.85	1.10	1.52	1.97	1.59	0.65	1.82	0.75	0.36	0.58
Debt-free, Cash-free Net Working Capital (DFCFNWC)	31	27	28	25	20	17	17	19	12	9.96
Debt-free Net Working Capital (DFNWC)	268	264	262	150	148	149	164	173	117	123
Net Working Capital (NWC)	268	264	262	150	148	149	164	173	117	123
Net Nonoperating Expense (NNE)	-0.10	-0.12	0.25	1.63	1.58	3.66	4.27	4.04	5.12	5.65
Net Nonoperating Obligations (NNO)	-226	-227	-223	-124	-126	-130	-126	-111	-63	-69
Total Depreciation and Amortization (D&A)	-2.11	-1.63	-1.25	-0.37	-0.49	-0.46	-0.52	-0.12	0.32	0.73
Debt-free, Cash-free Net Working Capital to Revenue	21.96%	21.05%	24.59%	24.61%	22.81%	22.36%	25.05%	32.75%	23.50%	24.09%
Debt-free Net Working Capital to Revenue	191.49%	205.88%	227.13%	148.60%	165.59%	194.56%	244.59%	300.23%	239.40%	297.01%
Net Working Capital to Revenue	191.49%	205.88%	227.13%	148.60%	165.59%	194.56%	244.59%	300.23%	239.40%	297.01%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.14)	($0.16)	($0.16)	($0.25)	($0.24)	($0.35)	($0.40)	($0.42)	($0.55)	($0.61)
Adjusted Weighted Average Basic Shares Outstanding	38.87M	39.79M	38.46M	36.84M	34.46M	35.66M	34.50M	31.64M	27.66M	27.67M
Adjusted Diluted Earnings per Share	($0.14)	($0.16)	($0.16)	($0.25)	($0.24)	($0.35)	($0.40)	($0.42)	($0.55)	($0.61)
Adjusted Weighted Average Diluted Shares Outstanding	38.87M	39.79M	38.46M	36.84M	34.46M	35.66M	34.50M	31.64M	27.66M	27.67M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	40.49M	40.30M	39.68M	37.20M	36.99M	35.86M	35.64M	33.98M	33.78M	27.72M
Normalized Net Operating Profit after Tax (NOPAT)	-6.04	-6.46	-5.83	-7.47	-7.60	-8.76	-9.54	-9.17	-10	-11
Normalized NOPAT Margin	-15.02%	-18.29%	-16.72%	-25.31%	-26.58%	-39.45%	-45.83%	-52.42%	-65.22%	-88.55%
Pre Tax Income Margin	-14.74%	-17.91%	-17.38%	-30.80%	-32.17%	-55.87%	-66.21%	-75.54%	-97.00%	-133.32%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-2,157.25	-1,845.20	-1,388.83	-1,778.33	-3,617.00	-7.64	-7.06	-8.69	-10.33	-12.28
NOPAT to Interest Expense	-1,510.08	-1,291.64	-972.18	-1,244.83	-2,531.90	-5.35	-4.94	-6.08	-7.23	-8.60
EBIT Less CapEx to Interest Expense	-2,369.00	-2,065.80	-1,642.67	-2,106.17	-4,147.33	-8.04	-8.00	-9.19	-10.58	-12.73
NOPAT Less CapEx to Interest Expense	-1,721.83	-1,512.24	-1,226.02	-1,572.67	-3,062.23	-5.75	-5.89	-6.58	-7.48	-9.05
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-2.80%	-2.42%	-1.08%	-0.88%	-1.28%	-1.71%	-2.00%	-1.31%	-0.88%	-0.08%

Frequently Asked Questions About RxSight's Financials

When does RxSight's fiscal year end?

According to the most recent income statement we have on file, RxSight's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has RxSight's net income changed over the last 2 years?

RxSight's net income appears to be on a downward trend, with a most recent value of -$27.46 million in 2024, falling from -$66.76 million in 2022. The previous period was -$48.61 million in 2023. View RxSight's forecast to see where analysts expect RxSight to go next.

What is RxSight's operating income?

RxSight's total operating income in 2024 was -$36.86 million, based on the following breakdown:

Total Gross Profit: $98.94 million
Total Operating Expenses: $135.80 million

How has RxSight revenue changed over the last 2 years?

Over the last 2 years, RxSight's total revenue changed from $49.01 million in 2022 to $139.93 million in 2024, a change of 185.5%.

How much debt does RxSight have?

RxSight's total liabilities were at $37.33 million at the end of 2024, a 68.2% increase from 2023, and a 38.1% decrease since 2022.

How much cash does RxSight have?

In the past 2 years, RxSight's cash and equivalents has ranged from $9.69 million in 2023 to $16.71 million in 2024, and is currently $16.71 million as of their latest financial filing in 2024.

How has RxSight's book value per share changed over the last 2 years?

Over the last 2 years, RxSight's book value per share changed from 3.24 in 2022 to 6.98 in 2024, a change of 115.2%.

Related Companies

This page (NASDAQ:RXST) was last updated on 5/24/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

RxSight (RXST) Financials

Frequently Asked Questions About RxSight's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

RxSight (RXST) Financials

Annual Income Statements for RxSight

Quarterly Income Statements for RxSight

Annual Cash Flow Statements for RxSight

Quarterly Cash Flow Statements for RxSight

Annual Balance Sheets for RxSight

Quarterly Balance Sheets for RxSight

Annual Metrics And Ratios for RxSight

Quarterly Metrics And Ratios for RxSight

Frequently Asked Questions About RxSight's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools